Nuvalent, Inc.(NASDAQ:NUVL) 
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant muta...
Website: http://www.nuvalent.com
Founded: 2017
CEO: James Porter
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 66.70
H 68.03
L 64.54
C 65.74
V 582,527
10EMA 65.74
20EMA 65.74
60EMA 65.74
120EMA 65.74
250EMA 65.74